---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-087461"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2025-09-15T23:59:59+00:00"
generated_at: "2026-05-17T06:40:33.384884+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics acquires eXIthera's Factor XIa inhibitors for up to $15M in milestones

## Summary
- Acquires frunexian (Phase 2-ready IV FXIa) and EP-7327 (IND-ready oral FXIa) from eXIthera.
- Total contingent milestone payments up to $15M plus royalties on global sales; $50K cash paid at closing.
- Deal closed September 12, 2025; Cadrenal now sole developer of both a VKA (tecarfarin) and FXIa inhibitors.
- Plans Phase 2 study for frunexian in complex cardiac surgery with first patient expected in 1Q27.
- eXIthera to receive 2% royalty on net sales outside China and 50% of sublicense royalties from Haisco.

## SEC filing metadata
- accession: 0001213900-25-087461
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2025-09-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390025087461/0001213900-25-087461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390025087461/ea0257138-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-087461
- JSON: https://secwatch.observer/filing/0001213900-25-087461.json
- Plain text: https://secwatch.observer/filing/0001213900-25-087461.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.